Equities Analysts Offer Predictions for IONS FY2028 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Equities research analysts at Leerink Partnrs reduced their FY2028 earnings per share estimates for Ionis Pharmaceuticals in a report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of $1.32 for the year, down from their previous estimate of $1.47. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.73) per share.

Several other research firms have also issued reports on IONS. StockNews.com upgraded Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. BMO Capital Markets lowered Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the company from $67.00 to $60.00 in a research note on Friday, August 2nd. Bank of America boosted their price target on Ionis Pharmaceuticals from $67.00 to $68.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Guggenheim dropped their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $60.71.

Ionis Pharmaceuticals Trading Up 1.9 %

IONS opened at $39.19 on Friday. The business’s 50-day moving average is $40.65 and its two-hundred day moving average is $42.92. Ionis Pharmaceuticals has a 1 year low of $35.95 and a 1 year high of $54.44. The company has a current ratio of 7.61, a quick ratio of 7.51 and a debt-to-equity ratio of 4.67.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.21. The firm had revenue of $134.00 million during the quarter, compared to the consensus estimate of $128.99 million. Ionis Pharmaceuticals had a negative return on equity of 113.42% and a negative net margin of 44.58%.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in IONS. Landscape Capital Management L.L.C. acquired a new position in Ionis Pharmaceuticals during the third quarter worth approximately $1,019,000. Grandfield & Dodd LLC grew its holdings in Ionis Pharmaceuticals by 2.2% during the third quarter. Grandfield & Dodd LLC now owns 34,813 shares of the company’s stock worth $1,395,000 after acquiring an additional 760 shares during the period. Advisors Asset Management Inc. boosted its position in Ionis Pharmaceuticals by 21.0% during the third quarter. Advisors Asset Management Inc. now owns 6,140 shares of the company’s stock worth $246,000 after purchasing an additional 1,066 shares in the last quarter. Commerce Bank boosted its position in Ionis Pharmaceuticals by 1.6% during the third quarter. Commerce Bank now owns 77,553 shares of the company’s stock worth $3,107,000 after purchasing an additional 1,211 shares in the last quarter. Finally, Prospera Private Wealth LLC purchased a new stake in Ionis Pharmaceuticals during the third quarter worth $42,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.